Reliable subtype classification of diffuse large B-cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay.
作者信息
Jais Jean-Philippe, Molina Thierry Jo, Ruminy Philippe, Gentien David, Reyes Cecile, Scott David W, Rimsza Lisa M, Wright George, Gascoyne Randy D, Staudt Louis M, Haioun Corinne, Tilly Herve, Gaulard Philippe, Salles Gilles A, Jardin Fabrice, Leroy Karen
机构信息
AP-HP, Cochin and Necker Hospitals and Paris Descartes University, France.
Paris Descartes University, EA 7324, France.
出版信息
Haematologica. 2017 Oct;102(10):e404-e406. doi: 10.3324/haematol.2017.166827. Epub 2017 Jul 4.
Abstract
摘要
相似文献
1
Reliable subtype classification of diffuse large B-cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay.利用Lymph2Cx基因表达分析对GELA LNH2003试验中的弥漫性大B细胞淋巴瘤样本进行可靠的亚型分类。
Haematologica. 2017 Oct;102(10):e404-e406. doi: 10.3324/haematol.2017.166827. Epub 2017 Jul 4.
2
Comparison of protein-based cell-of-origin classification to the Lymph2Cx RNA assay in a cohort of diffuse large B-cell lymphomas in Malaysia.比较基于蛋白质的细胞起源分类与淋巴 2Cx RNA 检测在马来西亚弥漫性大 B 细胞淋巴瘤队列中的应用。
J Clin Pathol. 2018 Mar;71(3):215-220. doi: 10.1136/jclinpath-2017-204548. Epub 2017 Aug 3.
3
Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm.通过Lymph2Cx检测确定弥漫性大B细胞淋巴瘤的起源细胞：比汉斯算法更好的预后指标。
Oncotarget. 2017 Mar 28;8(13):22014-22022. doi: 10.18632/oncotarget.15782.
4
Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma.弥漫性大B细胞淋巴瘤中与临床分子亚型及预后相关的免疫相关长链非编码RNA生物标志物的发现与验证
Mol Cancer. 2017 Jan 19;16(1):16. doi: 10.1186/s12943-017-0580-4.
5
Molecular Classification of Diffuse Large B-cell Lymphoma: What Is Clinically Relevant?弥漫性大B细胞淋巴瘤的分子分类：哪些具有临床相关性？
Hematol Oncol Clin North Am. 2016 Dec;30(6):1163-1177. doi: 10.1016/j.hoc.2016.07.001.
6
New insights into the biology of molecular subtypes of diffuse large B-cell lymphoma and Burkitt lymphoma.弥漫性大 B 细胞淋巴瘤和伯基特淋巴瘤分子亚型生物学的新见解。
Best Pract Res Clin Haematol. 2012 Mar;25(1):3-12. doi: 10.1016/j.beha.2012.01.003. Epub 2012 Feb 8.
7
Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.在德国高级非霍奇金淋巴瘤研究组的前瞻性临床试验中，针对弥漫性大 B 细胞淋巴瘤进行治疗，探讨了细胞起源分类和 MYC/BCL2 双表达状态的临床影响。
J Clin Oncol. 2017 Aug 1;35(22):2515-2526. doi: 10.1200/JCO.2016.70.3660. Epub 2017 May 19.
8
Lymphoma classification update: B-cell non-Hodgkin lymphomas.淋巴瘤分类更新：B细胞非霍奇金淋巴瘤
Expert Rev Hematol. 2017 May;10(5):405-415. doi: 10.1080/17474086.2017.1318053. Epub 2017 Apr 24.
9
[Detection for subtype-specific genomic/genetic alterations in diffuse large B-cell lymphoma (DLBCL)].
Rinsho Ketsueki. 2008 Feb;49(2):73-81.
10
Molecular heterogeneity of diffuse large B-cell lymphoma.
Hematol J. 2004;5 Suppl 3:S144-8. doi: 10.1038/sj.thj.6200441.
引用本文的文献
1
Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201.伊布替尼联合标准预处理方案，并在自体造血干细胞移植后作为维持治疗用于复发或难治性活化B细胞型弥漫性大B细胞淋巴瘤：美国多中心双盲随机III期研究Alliance A051301/BMT-CTN 1201的初步分析
Leuk Lymphoma. 2025 Jul 9:1-10. doi: 10.1080/10428194.2025.2525982.
2
Evolving molecular classification of aggressive B-cell lymphoma.侵袭性B细胞淋巴瘤不断发展的分子分类
Histopathology. 2025 Jan;86(1):94-105. doi: 10.1111/his.15350. Epub 2024 Nov 15.
3
Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications.利妥昔单抗时代弥漫性大B细胞淋巴瘤的预后分子生物标志物及其治疗意义。
Ther Adv Hematol. 2021 May 24;12:20406207211013987. doi: 10.1177/20406207211013987. eCollection 2021.
4
Predictive and Prognostic Molecular Factors in Diffuse Large B-Cell Lymphomas.弥漫性大 B 细胞淋巴瘤的预测和预后分子因素。
Cells. 2021 Mar 18;10(3):675. doi: 10.3390/cells10030675.
5
Molecular Genetics of Relapsed Diffuse Large B-Cell Lymphoma: Insight into Mechanisms of Therapy Resistance.复发性弥漫性大B细胞淋巴瘤的分子遗传学：对治疗耐药机制的洞察
Cancers (Basel). 2020 Nov 28;12(12):3553. doi: 10.3390/cancers12123553.
6
A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL.一种经过改良的基于细胞起源的分类器，结合靶向 NGS 和人工智能，在弥漫性大 B 细胞淋巴瘤中显示出强大的预测价值。
Blood Adv. 2020 Jul 28;4(14):3391-3404. doi: 10.1182/bloodadvances.2020001949.
7
Molecular Complexity of Diffuse Large B-Cell Lymphoma: Can It Be a Roadmap for Precision Medicine?弥漫性大B细胞淋巴瘤的分子复杂性：它能成为精准医学的路线图吗？
Cancers (Basel). 2020 Jan 11;12(1):185. doi: 10.3390/cancers12010185.
8
Discriminant analysis and machine learning approach for evaluating and improving the performance of immunohistochemical algorithms for COO classification of DLBCL.用于评估和改进弥漫性大 B 细胞淋巴瘤 COO 分类免疫组化算法性能的判别分析和机器学习方法。
J Transl Med. 2019 Jun 11;17(1):198. doi: 10.1186/s12967-019-1951-y.
9
Dissecting diffuse large B-cell lymphomas of the "not otherwise specified" type: the impact of molecular techniques.
F1000Res. 2018 Dec 21;7. doi: 10.12688/f1000research.16755.1. eCollection 2018.
本文引用的文献
1
Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study.弥漫性大 B 细胞淋巴瘤中的下一代测序凸显了分子差异和治疗机会：LYSA 研究。
Clin Cancer Res. 2016 Jun 15;22(12):2919-28. doi: 10.1158/1078-0432.CCR-15-2305. Epub 2016 Jan 27.
2
Precision medicine in diffuse large B-cell lymphoma: hitting the target.弥漫性大B细胞淋巴瘤中的精准医学：命中靶点。
Haematologica. 2015 Aug;100(8):989-93. doi: 10.3324/haematol.2015.128371.
3
Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies.通过数字基因表达确定福尔马林固定石蜡包埋组织活检中弥漫性大B细胞淋巴瘤细胞起源的预后意义
J Clin Oncol. 2015 Sep 10;33(26):2848-56. doi: 10.1200/JCO.2014.60.2383. Epub 2015 Aug 3.
4
Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity.弥漫性大 B 细胞淋巴瘤：在临床和生物学异质性的背景下优化治疗结局。
Blood. 2015 Jan 1;125(1):22-32. doi: 10.1182/blood-2014-05-577189. Epub 2014 Dec 11.
5
Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.年轻的非生发中心 B 细胞样弥漫性大 B 细胞淋巴瘤患者从 ACVBP 联合利妥昔单抗强化化疗中获益优于 CHOP 联合利妥昔单抗：来自 Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma 研究协会 III 期试验 LNH 03-2B 的数据分析。
J Clin Oncol. 2014 Dec 10;32(35):3996-4003. doi: 10.1200/JCO.2013.54.9493. Epub 2014 Nov 10.
6
Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue.使用福尔马林固定石蜡包埋组织中的基因表达来确定弥漫性大 B 细胞淋巴瘤的细胞起源亚型。
Blood. 2014 Feb 20;123(8):1214-7. doi: 10.1182/blood-2013-11-536433. Epub 2014 Jan 7.
7
The molecular pathogenesis of primary mediastinal large B-cell lymphoma.原发性纵隔大 B 细胞淋巴瘤的分子发病机制。
Blood. 2011 Sep 8;118(10):2659-69. doi: 10.1182/blood-2011-05-326538. Epub 2011 Jun 23.
8
Automated extraction of DNA and RNA from a single formalin-fixed paraffin-embedded tissue section for analysis of both single-nucleotide polymorphisms and mRNA expression.从单个福尔马林固定石蜡包埋组织切片中自动提取 DNA 和 RNA，用于分析单核苷酸多态性和 mRNA 表达。
Clin Chem. 2010 Dec;56(12):1845-53. doi: 10.1373/clinchem.2010.151233. Epub 2010 Oct 14.
9
Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response.弥漫性大B细胞淋巴瘤的分子谱分析确定了多种明确的亚型，其中一种以宿主炎症反应为特征。
Blood. 2005 Mar 1;105(5):1851-61. doi: 10.1182/blood-2004-07-2947. Epub 2004 Nov 18.
10
Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma.原发性纵隔B细胞淋巴瘤的分子诊断确定了与霍奇金淋巴瘤相关的弥漫性大B细胞淋巴瘤的一个临床预后良好的亚组。
J Exp Med. 2003 Sep 15;198(6):851-62. doi: 10.1084/jem.20031074.
Zotero 插件